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A B S T R A C TObjective: This study aimed to evaluate the factors that are associ-
ated with positive (supporting public funding) and negative recom-
mendations of the Agency for Health Technology Assessment in
Poland. Methods: Two independent analysts reviewed all the recom-
mendations publicly available online before October 7, 2011. For each
recommendation, predeﬁned decision rationales, that is, clinical
efﬁcacy, safety, cost-effectiveness, and formal aspects, were sought,
either advocating or discouraging the public ﬁnancing. In the analysis,
we used descriptive statistics and a logistic regression model so as to
identify the association between predeﬁned criteria and the recom-
mendation being positive. Results: We identiﬁed 344 recommenda-
tions—218 positive (62.8%) and 126 negative (37.2%). Negative
recommendations were better justiﬁed and also the comments were
less ambiguous in accordance with the recommendation (except for
clinical efﬁcacy). In general, the speciﬁed criteria supported the
decision (either positive or negative) in 209 (60.8%), 107 (31.1%), 124
(36.0%), 96 (27.9%), and 61 (17.7%) recommendations, respectively, and
ran contrary to the actual decision in the remaining ones. Thresholdsee front matter Copyright & 2013, International S
r Inc.
1016/j.vhri.2013.05.002
rest: The authors have indicated that they have n
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ondence to: Maciej Niewada, Department of Experim
ieście 26/28, 00-927 Warsaw, Polandvalues for either cost-effectiveness or budget impact distinguishing
positive from negative recommendations could not be speciﬁed. The
following parameters reached statistical signiﬁcance in logistic regres-
sion: clinical efﬁcacy (both explicitly positive and explicitly negative
evaluations impacted in opposite directions), lack of impact on hard
end points, unfavorable safety proﬁle, cost-effectiveness results, and
formal shortcomings (all reduced the probability of a positive recom-
mendation). Conclusions: Decision making of the Agency for Health
Technology Assessment in Poland is multicriterial, and its results
cannot be easily decomposed into simple associations or easily
predicted. Still, efﬁcacy and safety seem to contribute most to ﬁnal
recommendations.
Keywords: decision making, health technology assessment,
incremental cost-effectiveness ratio, reimbursement.
Copyright & 2013, International Society for Pharmacoeconomics and
Outcomes Research (ISPOR). Published by Elsevier Inc.Introduction
Health technology assessment (HTA) agencies play a vital role in
the decision-making process, whether or not to reimburse given
health technologies. These agencies are expected to be guided by
medical, economic, and ethical criteria and to account for limited
resources and sometimes limited evidence regarding the proﬁle
of assessed technologies. Therefore, there are many possible
drivers for the ﬁnal decision.
The aim of the current scientiﬁc project was in general to
detect the criteria that can be considered important for the
Agency for Health Technology Assessment in Poland (AHTAPol),
and in particular to try to ﬁnd the characteristics of HTA reports
that are associated with positive and negative recommendations.
The AHTAPol was established in 2005 by the Ministry of
Health as a ﬁrst of its kind of institution in Central and Eastern
Europe. Since 2009, the AHTAPol is deﬁned as a legal andindependent entity playing a key role in reimbursement decision
making. The most important role of the AHTAPol is to prepare
recommendations for and support decision making by the Min-
istry of Health on ﬁnancing health care services from the public
budget. The AHTAPol assesses and appraises all medical tech-
nologies, drugs, devices, and other services that are claiming
public funding. The role of the AHTAPol covers the assessment
and appraisal of the HTA reports including systematic review of
clinical ﬁndings, economic evaluation, and budget impact anal-
ysis, majority of which are submitted by the pharmaceutical
industry. Assessment is provided by a team of analysts and based
on the Polish HTA guidelines (ﬁrst issued in 2007 and reviewed in
2009) [1]. Appraisal is completed by the Consultative Council
(transformed into the Transparency Council with the beginning
of 2012), a team of highly qualiﬁed and experienced specialists,
and the president of the AHTAPol. Final judgment is made in the
speciﬁc context of the alternative options available, socialociety for Pharmacoeconomics and Outcomes Research (ISPOR).
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national health priorities, and social and ethical aspects. Based
on AHTAPol recommendations, reimbursement decisions are
made by the Ministry of Health following negotiations with
pharmaceutical industry representatives.
Recommendations issued by the AHTAPol have evolved over
time. The new types of recommendations (i.e., conditional,
temporal, combined, and others [2]) were introduced. Legal back-
ground of recommendations has also changed and currently
statements by the Consultative Council and ﬁnal recommenda-
tions by the President of the AHTAPol are issued [3].
The current article can be located in the line of research
established by a classical article of Devlin and Parkin [4] and a
study by Towse [5]. Devlin and Parker analyzed past decisions
made by the National Institute for Health and Clinical Excellence
(NICE) in the United Kingdom to determine factors that were
associated with positive decisions, and in particular the thresh-
old level for the incremental cost-effectiveness ratio (ICER). In
their study, they managed to detect that the threshold level
probably lies above approximately 35,000 GBP. The study of
Devlin and Parker motivated subsequent articles. And so,
Tappenden et al. [6] tried to identify the preferences of the
members of NICE Appraisal Committees by using a
questionnaire-based study. They concentrated more on the
ethical issues, that is, on the impact of such variables as baseline
quality of life or age of the beneﬁciaries. Dakin et al. [7]
introduced multinomial approach to these kinds of studies,
accounting for conditional approval by NICE.Methods
Material
The analysis covered all recommendations and statements of the
Consultative Council of the AHTAPol issued following two sepa-
rate regulations (the Ordinance of the Minister of Health dated
September 10, 2009, and the Act on Healthcare Services Financing
From Public Funds) and available on the ofﬁcial Web site of the
agency (http://www.aotm.gov.pl) before October 7, 2011. It may be
somewhat misleading that we call “a recommendation” both the
text published by the AHTAPol and the ﬁnal conclusion thereof.
We do not call the latter “a decision” because this is made only by
the Ministry of Health and need not agree with the AHTAPol
recommendation. At the same time, we decided to analyze
recommendations, not decisions, because the decisions are not
accompanied by any justiﬁcations and thus would be difﬁcult to
spot any regularities.Inclusion and exclusion criteria
All recommendations and statements were included with the
exception of collective recommendations for dental interventions
(covering not a single technology but a group of technologies).
Some recommendations were explained either poorly or not at all
—then the recommendation was excluded altogether.Table 1 – Data interpretation for predeﬁned criteria dete
Positive recommendations
Criterion Positive data (consistent
impact on ﬁnal judgment)
Negative data (not
driving ﬁnal judgmen
AHTAPol, Agency for Health Technology Assessment in Poland.Analysis—Data Extraction and Interpretation
Only recommendations’ texts were analyzed, neither HTA reports
nor critical appraisal, which in most cases were not available on
the ofﬁcial Web site of the AHTAPol. For every recommendation,
the following data were extracted: medical technology being
evaluated, medical therapeutic area in which the technology
reimbursement was appealed, and the year of issuing the
recommendation. Different types of AHTAPol recommendations
(e.g., supporting or rejecting funding, conditional, temporary,
and combined) were redeﬁned into statements of limited or
no ﬁnancing technology (negative recommendations) or ones
supporting ﬁnancing or increase in funding (positive recom-
mendations).
Each recommendation was evaluated independently by two
researchers by using predeﬁned criteria listed below (language
specialist with experience in auditing of HTA reports and HTA
specialist). Disagreements were resolved by discussion. For every
recommendation (positive or negative), it was classiﬁed whether
the ﬁnal recommendation was supported or discouraged by each
criterion. Table 1 presents the data interpretation. Consistency
was found if for a particular criterion positive and negative
ﬁndings were reported and explicitly referred to support positive
and negative recommendations, respectively. For other situa-
tions, we interpreted the criterion as not reﬂected in the ﬁnal
judgment. Following pilot analysis of the AHTAPol recommen-
dations, clinical, economic, and formal criteria used to judge ﬁnal
statements were distinguished. In a few recommendations,
rationales used to judge ﬁnal statement could not be classiﬁed
as the above-listed criteria and were not deﬁned separately.
Clinical criteria
The importance of general relative efﬁcacy and safety over
comparators in decisions’ reasoning by the Consultative Council
was recognized in pilot analysis. Thus, the clinical criteria were
further split into three subcriteria: the efﬁcacy (beneﬁt over the
comparator used in the analysis—an active treatment or pla-
cebo), safety, and the impact of the technology on clinical hard
end points (which were treated separately as anticipated signiﬁ-
cant driver of clinical decision making). Hard end points were
deﬁned following reviewed Polish guidelines for HTA as clinically
signiﬁcant end points, playing an important role in a given
disease, that is, deaths, cases or recoveries, quality of life, adverse
effects (divided into serious and nonserious), or medical events
[1]. The issue of difference between the efﬁcacy, studied in
clinical trials, and effectiveness, observed in real life settings,
was not taken up explicitly in any recommendation; thus, it was
not addressed in our analysis.
Economic criteria
Economic criteria were also further split into two subcriteria:
cost-effectiveness and the impact on the payer’s budget. The
evaluation of the technology’s cost-effectiveness signiﬁcance was
based on values for cost per quality-adjusted life-year (QALY)
or life-year gained (LYG) reported in the recommendations
and assumed cost-effectiveness threshold of three times
the gross domestic product per capita (∼83,239 PLN) [7]. Thermining the AHTAPol recommendations.
Negative recommendations
t)
Negative data (consistent
impact on ﬁnal judgment)
Positive data (not
driving ﬁnal judgment)
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Consultative Council was analyzed independently of the statis-
tical analysis of cost per QALY or LYG values reported in
recommendations.
The extent of the medical technology reimbursement impact
on the payer’s budget and its inﬂuence on the recommendations
were also analyzed. Because there was no clear deﬁnition of a
large or small impact on the budget, we could extract only the
Consultative Council perception and interpretation of budget
impact data and analyze independently estimated annual mean
payer’s expenses reported in recommendations.Formal criteria
Another group of rationales recognized in pilot analysis, which
inﬂuenced the issuing of the positive or negative recommenda-
tion by the AHTAPol Consultative Council, was of legal or
procedural nature and encompassed failure to meet require-
ments of the AHTAPol for HTA reports or deﬁciencies of the
reports submitted to the agency, submission of reports after the
deadline, the discrepancy between expert opinions and analyses
submitted by pharmaceutical industry, submission for unauthor-
ized (off-label) use, and so forth.
Statistical Analysis
We compared frequencies of values for binary criteria and means
for continuous ones between positive and negative recommen-
dations. Mean values were compared with unpaired t test with
separate variance estimation. We performed multivariate analy-
sis by using logistic regression to determine the association
between criteria values and ﬁnal recommendation. In this
approach, we redeﬁned the binary criteria to denote that a given
criterion is favorable or unfavorable for technology (rather than
agrees or not with the ﬁnal recommendation). Because for many
recommendations, there was neither a favorable nor an unfav-
orable comment, for each criterion we introduced two binary
variables that were used in econometric modeling—denoting,
respectively, that a favorable, unfavorable comment is presented
in the recommendation text. Obviously, both these variables
could be equal to zero, but not to one for any single recommen-
dation. While building the logistic regression model, we removed
individually variables that were not statistically signiﬁcant
(α ¼ 0.05).Table 2 – Summary of the impact of different criteria on
Criteria Positive recommendations (n
n (%)*
Clinical
Efﬁcacy 141 (64.7)
Impact on hard end points 59 (27.1) 4
Safety 67 (30.7) 2
Economic
Cost-effectiveness 40 (18.3) 4
Budget impact 18 (8.3)
Other
Formal issues 0 3
AHTAPol, Agency for Health Technology Assessment in Poland.
 Number (%) of positive recommendations that referred directly to the
† Number (%) of positive recommendations issued despite the explicitly r
criteria.
‡ Number (%) of negative recommendations referred to unfavorable proﬁ
§ Number (%) of negative recommendations issued despite the explicit
criteria.Results
Three hundred forty-four recommendations were analyzed. We
identiﬁed 218 positive (62.8%) and 126 negative (37.2%) recom-
mendations. Eighty-nine recommendations addressed oncologi-
cal technologies, mostly drugs. Other most common
recommendations were identiﬁed for psychiatry, cardiology,
neurology, rheumatology, and diabetes (32, 24, 20, 19, and 17
recommendations, respectively). Only 14 recommendations were
dedicated to technologies authorized for rare diseases.
Clinical efﬁcacy, impact of hard end points, safety, cost-
effectiveness, and formal issues were explicitly discussed by
the Consultative Council in 238 (69.2%), 169 (49.1%), 155 (45.1%),
140 (40.7%), and 47 (13.7%) recommendations, respectively. From
this perspective, clinical issues seem to be more important than
economic ones. Exact ICER values could be found for 106 (30.8%)
recommendations, while exact budget impact estimates could be
found for 193 (56.1%) recommendations.
In general, we observed that in the recommendations texts
the elements that support the ﬁnal recommendation were
explicitly stated more often. The clinical efﬁcacy, impact of hard
end points, safety, cost-effectiveness, and formal issues have
been explicitly pointed by the Consultative Council to justify 209
(60.8%), 107 (31.1%), 124 (36.0%), 96 (27.9%), and 61 (17.7%)
recommendations, respectively. However, 29 (8.4%), 62 (18.0%),
31 (9.0%), 44 (12.8%), and 36 (10.5%) recommendations were made
against the results reported on the clinical efﬁcacy, impact of
hard end points, safety, cost-effectiveness, and formal issues,
respectively. This data are presented in Table 2.
In addition, these numbers are presented separately for
positive and negative recommendations in Figures. 1 and 2. The
following interpretations can be made. First, Consultative Council
tries explicitly to give rationale especially for negative recom-
mendations—the percentage of recommendations accompanied
with a comment on criterion that backs this recommendation up
is higher for negative recommendations (stacked columns higher
in Fig. 2), except for clinical efﬁcacy. This type of reasoning is
more often presented for positive recommendations. Second, the
Consultative Council is more reluctant to present arguments
opposing the ﬁnal opinion in case of negative recommendations
(stacked columns consisting mostly of the “agree” part). In other
words, in the case of positive recommendations, the Council
tones down the message more often. Again, the clinical efﬁcacy ispositive and negative AHTAPol recommendations.
¼ 218) Negative recommendations (n ¼ 126)
n (%)† n (%)‡ n (%)§
9 (4.1) 68 (54) 20 (15.9)
3 (19.7) 48 (38.1) 19 (15.1)
1 (9.6) 57 (45.2) 10 (7.9)
1 (18.8) 56 (44.4) 3 (2.4)
8 (3.7) 17 (13.5) 4 (3.2)
5 (10.2) 61 (17.7) 0
favorable proﬁle of technologies in the analyzed criterion.
eferred lack of beneﬁt (advantage) of the technology for the analyzed
le of the technology for the analyzed criteria.
ly referred beneﬁt (advantage) of the technology for the analyzed
Fig. 1 – Number of references to single criteria for positive recommendations. BI, budget impact; CE, cost-effectiveness.
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ﬁnal recommendation for positive ones than for negative ones.
Third, the criteria that are most ambiguous for positive
recommendations (dashed and solid parts almost equal in
stacked columns) are the impact on hard end points and cost-
effectiveness—among all the positive recommendations that
mention these criteria in only 57.8% and 49.4%, respectively,
these criteria support the ﬁnal recommendation. For example, for
clinical efﬁcacy in 94% of the cases it is presented for a positive
recommendation, it is also favorable for the technology. What is
quite intuitive is that formal issues are almost exclusively
brought forward in a fashion unfavorable for a technology, and
much more frequently in negative recommendations. Except for
that, it is cost-effectiveness that is usually casting an unfavorable
light on the technology.
We also calculated how much the relative frequencies of
favorable or unfavorable comments differ for positive or negative
recommendations. We calculated the odds ratio (OR) for a criterion
being favorable between positive and negative recommendations
(by deﬁnition identical to the OR of a recommendation beingFig. 2 – Number of references to single criteria for negative recopositive between favorable and unfavorable criterion). Clinical
efﬁcacy changes most between two types of recommendations
(OR ¼ 53.3) followed by safety and cost-effectiveness (OR ¼ 18.2
both), and then impact on hard end points (OR ¼ 3.5). The
composition for the formal issues criterion barely differs.
More in-depths analysis of economic ﬁndings, either cost-
effectiveness (mean cost per QALY or LYG) or budget impact
(mean annual payer’s spending) values, showed no difference in
mean values reported for positive and negative recommenda-
tions (P ¼ 0.9045 for ICER and ¼ 0.3868 for budget impact). No
clear relation between cost-effectiveness (Fig. 3) and budget
impact (Fig. 4) values and positive and negative recommenda-
tions rates was observed. This is the ﬁrst signal, before the
logistic regression, that threshold values either for cost-
effectiveness or for budget impact distinguishing positive and
negative recommendations cannot be speciﬁed.
Finally, a logistic regression model showed joint associations
between analyzed criteria and ﬁnal recommendation (being pos-
itive; Table 3). Clinical efﬁcacy seems to be the most important
variable—impacting both when explicitly stated to be favorable ormmendations. BI, budget impact; CE, cost-effectiveness.
Fig. 3 – Distribution of ICER values for positive and negative
recommendations. ICER, incremental cost-effectiveness
ratio.
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when presented in an unfavorable fashion.Discussion
In deciding whether or not to recommend the reimbursement of
technology from the public budget, the AHTAPol Consultative
Council seems to be considering many aspects of the problem.
Although the AHTAPol has adopted a standardized approach and
continuously publishes key documents online, in case of individ-
ual decisions, various aspects of the assessment were weighted
differently. It is still therefore a challenge to deﬁne a clear pattern
of decision making by the AHTAPol.
The most important criterion found to be used as a rationale
to back up the decisions by the AHTAPol Consultative Council
was clinical efﬁcacy. It is called for most often in the recom-
mendations texts (69.4%). It is illustrated by the number of
positive recommendations guided by the proved efﬁcacy andFig. 4 – Distribution of budget impact values for positive and
negative recommendations.negative ones resulting from the lack of it, which altogether
accounted for 61% of all recommendations. Safety and cost-
effectiveness contributed less often to justiﬁcation of the ﬁnal
decisions. To be granted with positive recommendation, technol-
ogy should prove unequivocal efﬁcacy. Almost twice less often,
the impact on hard end points was supportive for the recom-
mendations. Hard end points are hierarchical, which was
reﬂected in the content of the recommendations. It is likely that
the Consultative Council of the ATHAPol appreciated information
on mortality more than on the quality-of-life beneﬁt, but it needs
further studies.
Another important criterion for reasoning the recommenda-
tions was safety for either negative or positive ones. The eco-
nomic proﬁle of the technology, that is, cost-effectiveness and
budget impact, was less often used to justify the ﬁnal decisions.
The cost-effectiveness seems not to be a sine qua non criterion
when issuing positive recommendations, because in 41 cases,
even though the council referred to the reports of an unfavorable
cost-effectiveness proﬁle, the recommendation was positive.
Such a nonstrict use of cost-effectiveness data was also reported
for NICE health technology coverage decisions [8]. NICE seems to
perceive cost-effectiveness as secondary to clinical efﬁcacy, and
proﬁtability is considered only if the technology has passed a
clinical effectiveness hurdle.
We failed to detect any empirical threshold value for cost-
effectiveness and budget impact analyses that would separate
positive and negative recommendations. Similar approach for
NICE decisions was based on modeling and produces inconsis-
tent results [9,10]. Studies indicated that NICE makes use of some
form of cost-effectiveness threshold but expressed concern about
its basis and its use in decision making [4]. In addition, sensitivity
analysis around cost-effectiveness represents a challenge in
making it accessible to those making decisions [11].
In our study, we follow most closely the approach by Devlin
and Parker, trying to detect factors associated with positive
recommendation, and among others, to ﬁnd the impact of ICER
on AHTAPol’s decisions. Both the explanatory variables and
interpretation, however, differ from above-mentioned studies.
And so we dispose over not the original reports but the recom-
mendations issued by the AHTAPol. These recommendations
usually contain information on the interpretation by the
AHTAPol whether a technology was shown in the original HTA
report to offer beneﬁts in each of the analyzed criteria. More
importantly, these descriptors are available only when AHTAPol
decides to include it in the recommendation text. Therefore, the
characteristics of the HTA report are often missing, and most
probably not missing in random. Therefore, we would hardly
interpret our analysis as ﬁnding predictors of AHTAPol’s deci-
sions, but rather ﬁnding regularities in the way its decisions are
rationalized.Table 3 – Logistic regression modeling results:
Variables associated with positive
recommendation.
Variable; only statistically
signiﬁcant predictors are listed
(all P values o0.005)
Odds ratio for positive
recommendation
Clinical efﬁcacy established 12.29
No evidence for impact on hard end
points
0.251579
Lack of clinical efﬁcacy 0.213248
Safety ambiguous or unfavorable 0.170623
No cost-effectiveness 0.187739
Formal shortcomings 0.21062
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decision criteria and the underlying evidence are necessary. A
decision support framework can allow a consistent approach to
appraising health care interventions and evidence-based
resource allocation as shown by incorporating multiple-criteria
decision analysis in HTA to support transparent and systematic
appraisal of health care interventions [12–15].
Limitations
Our analysis was based only on recommendation texts (predom-
inantly on recommendation justiﬁcation section); thus, indirect
conclusions on recommendation determinants could not be fully
objective. It should be emphasized that the recommendations
available on the Web site of the AHTAPol do not have a uniﬁed
structure that would allow a thoroughly consistent analysis.
Although the Consultative Council certainly evaluated all the
aspects of submissions, in the recommendations’ texts, presum-
ably selected and the most important elements determining the
decision were reported. For this reason, our evaluation of recom-
mendations is subject to some subjectivity, which we tried to
limit as far as possible by developing a common interpretation
driven by both language and technical interpretation of the
available documents. Our analysis, because of formal grounds,
deﬁned by available information (the text of individual recommen-
dations issued by the Consultative Council or the opinion of the
president), could not focus on all aspects that inﬂuenced issuing a
particular opinion, but only on those that appeared explicitly in the
recommendations’ text. We analyzed not only justiﬁcation sec-
tions, but all the recommendations’ document content; therefore,
some arguments not raised in the justiﬁcation but emphasized as
important could be also identiﬁed and analyzed.
In assessing the technology efﬁcacy it was taken into account
whether the Consultative Council found it satisfactory, regardless
of whether the effectiveness of the technology was compared
with placebo or an active comparator. Comparable efﬁcacy proﬁle
of the assessed intervention over its comparators, depending on
individual circumstances, might have been assessed by the
Council separately, that is, negatively, as an intervention that
did not add anything and represented only a burden on the
budget of the payer, or positively, as an intervention of similar
efﬁcacy to others used for the same therapeutic indication.
Difﬁculties in determining the signiﬁcance of a technology’s
cost-effectiveness resulted from alternative ways of expressing
the ICER, other than the cost of the QALY or the LYG, which made
interpretation practically impossible.Conclusions
The decision-making process of the AHTAPol Consultative Coun-
cil is a multifaceted and a multicriterial one, and its results
cannot be easily decomposed into simple associations nor can beeasily predicted. Still, efﬁcacy and safety proﬁle seem to contrib-
ute most to ﬁnal recommendations.
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